€2.89
0.14% today
Paris, May 14, 12:44 pm CET
ISIN
FR0004056851
Symbol
VLA
Sector
Industry

Valneva Stock price

€2.90
-0.29 9.21% 1M
+0.50 20.95% 6M
+0.74 34.04% YTD
-0.55 16.05% 1Y
-9.03 75.70% 3Y
-1.04 26.35% 5Y
-1.12 27.91% 10Y
Paris, Closing price Tue, May 13 2025
-0.02 0.62%
ISIN
FR0004056851
Symbol
VLA
Sector
Industry

Key metrics

Market capitalization €484.39m
Enterprise Value €542.55m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.92
P/S ratio (TTM) P/S ratio 2.60
P/B ratio (TTM) P/B ratio 2.69
Revenue growth (TTM) Revenue growth 21.64%
Revenue (TTM) Revenue €186.06m
EBIT (operating result TTM) EBIT €-80.79m
Free Cash Flow (TTM) Free Cash Flow €-74.13m
Cash position €152.99m
EPS (TTM) EPS €-0.52
P/E forward negative
P/S forward 2.55
EV/Sales forward 2.85
Show more

Is Valneva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Valneva Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Valneva forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Valneva forecast:

Buy
88%
Hold
13%

Financial data from Valneva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
186 186
22% 22%
100%
- Direct Costs 99 99
3% 3%
53%
92 92
68% 68%
49%
- Selling and Administrative Expenses 91 91
9% 9%
49%
- Research and Development Expense 76 76
29% 29%
41%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -81 -81
26% 26%
-43%
Net Profit -80 -80
230% 230%
-43%

In millions EUR.

Don't miss a Thing! We will send you all news about Valneva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Valneva SE is a biotech company. The firm engages in the development, production and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. The Technologies and Services segment regroups services and inventions in commercialization stage. The Vaccine Candidates segment consists of proprietary research and development programs aiming to generate new approvable products. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

Head office France
CEO Thomas Lingelbach
Employees 713
Founded 1999
Website www.valneva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today